chr2-47476371-C-T
Variant summary
Our verdict is Benign. Variant got -11 ACMG points: 0P and 11B. BP4_ModerateBP6_Very_StrongBP7
The NM_000251.3(MSH2):c.2010C>T(p.Pro670Pro) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000192 in 1,613,902 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).
Frequency
Consequence
NM_000251.3 synonymous
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -11 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152102Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000159 AC: 4AN: 251394Hom.: 0 AF XY: 0.00000736 AC XY: 1AN XY: 135878
GnomAD4 exome AF: 0.0000192 AC: 28AN: 1461800Hom.: 0 Cov.: 32 AF XY: 0.0000165 AC XY: 12AN XY: 727200
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152102Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74286
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Benign:3
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
PM2_Supporting, BP4, BP7 c.2010C>T, located in exon 13 of the MSH2 gene, is predicted to result in no amino acid change, p.(Pro670=) (BP7). This variant is found in 4/268249 alleles at a frequency of 0.0015% in the gnomAD v2.1.1 database, non-cancer dataset (PM2_supporting). Computational tools for this variant predicts no significant impact on splicing (BP4). To our knowledge, functional studies have not been reported for this variant. To our knowledge, this variant has not been reported in the literature in individuals affected with Lynch syndrome-related conditions. It has been identified in patients affected with breast cancer, in a patient affected with CRC showing conserved expression of MLH1, MSH2, MSH6 and PMS2 proteins, and in a patient affected with CRC showing loss of expression of MSH2 and MSH6 proteins and MSI-H (internal data). This variant has been reported in the ClinVar database (1x benign, 6x likely benign), but it has not been reported neither in InSiGHT nor in LOVD databases. Based on currently available information, the variant c.2010C>T should be considered a likely benign variant. -
- -
not specified Benign:2
This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -
- -
MSH2-related disorder Benign:1
This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -
Lynch syndrome 1 Benign:1
This variant is considered benign. This variant is a silent/synonymous amino acid change and it is not expected to impact splicing. -
Lynch syndrome Benign:1
- -
Hereditary nonpolyposis colorectal neoplasms Benign:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at